Global Gene Therapy On Cardiovascular Disease 麻豆原创 Research Report 2025

Publication ID:

PB503252784

Publication Date:

March 31, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The global market for Gene Therapy On Cardiovascular Disease was valued at US$ 322 million in the year 2024 and is projected to reach a revised size of US$ 28430 million by 2031, growing at a CAGR of 91.0% during the forecast period.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient"s cells instead of using drugs or surgery.
Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy On Cardiovascular Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy On Cardiovascular Disease.
The Gene Therapy On Cardiovascular Disease market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gene Therapy On Cardiovascular Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy On Cardiovascular Disease companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Segment by Application
Heart Disease
Vascular Disease
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Therapy On Cardiovascular Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Gene Therapy On Cardiovascular Disease 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Viral Gene Therapy
1.2.3 Non-Viral Gene Therapy
1.3 麻豆原创 by Application
1.3.1 Global Gene Therapy On Cardiovascular Disease 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Heart Disease
1.3.3 Vascular Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy On Cardiovascular Disease 麻豆原创 Perspective (2020-2031)
2.2 Global Gene Therapy On Cardiovascular Disease Growth Trends by Region
2.2.1 Global Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gene Therapy On Cardiovascular Disease Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Gene Therapy On Cardiovascular Disease Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Gene Therapy On Cardiovascular Disease 麻豆原创 Dynamics
2.3.1 Gene Therapy On Cardiovascular Disease Industry Trends
2.3.2 Gene Therapy On Cardiovascular Disease 麻豆原创 Drivers
2.3.3 Gene Therapy On Cardiovascular Disease 麻豆原创 Challenges
2.3.4 Gene Therapy On Cardiovascular Disease 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue
3.1.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue (2020-2025)
3.1.2 Global Gene Therapy On Cardiovascular Disease Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Gene Therapy On Cardiovascular Disease 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gene Therapy On Cardiovascular Disease Revenue
3.4 Global Gene Therapy On Cardiovascular Disease 麻豆原创 Concentration Ratio
3.4.1 Global Gene Therapy On Cardiovascular Disease 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy On Cardiovascular Disease Revenue in 2024
3.5 Global Key Players of Gene Therapy On Cardiovascular Disease Head office and Area Served
3.6 Global Key Players of Gene Therapy On Cardiovascular Disease, Product and Application
3.7 Global Key Players of Gene Therapy On Cardiovascular Disease, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy On Cardiovascular Disease Breakdown Data by Type
4.1 Global Gene Therapy On Cardiovascular Disease Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Gene Therapy On Cardiovascular Disease Forecasted 麻豆原创 Size by Type (2026-2031)
5 Gene Therapy On Cardiovascular Disease Breakdown Data by Application
5.1 Global Gene Therapy On Cardiovascular Disease Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Gene Therapy On Cardiovascular Disease Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Gene Therapy On Cardiovascular Disease 麻豆原创 Size (2020-2031)
6.2 North America Gene Therapy On Cardiovascular Disease 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Country (2020-2025)
6.4 North America Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy On Cardiovascular Disease 麻豆原创 Size (2020-2031)
7.2 Europe Gene Therapy On Cardiovascular Disease 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Country (2020-2025)
7.4 Europe Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy On Cardiovascular Disease 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Gene Therapy On Cardiovascular Disease 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy On Cardiovascular Disease 麻豆原创 Size (2020-2031)
9.2 Latin America Gene Therapy On Cardiovascular Disease 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy On Cardiovascular Disease 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Gene Therapy On Cardiovascular Disease 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Gene Therapy On Cardiovascular Disease 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Gene Therapy On Cardiovascular Disease Introduction
11.1.4 Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Gene Therapy On Cardiovascular Disease Introduction
11.2.4 Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Introduction
11.3.4 Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.3.5 Gilead Sciences Recent Development
11.4 Sarepta Therapeutics
11.4.1 Sarepta Therapeutics Company Details
11.4.2 Sarepta Therapeutics Business Overview
11.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Introduction
11.4.4 Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.4.5 Sarepta Therapeutics Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Gene Therapy On Cardiovascular Disease Introduction
11.6.4 Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.6.5 Amgen Recent Development
11.7 Spark Therapeutics
11.7.1 Spark Therapeutics Company Details
11.7.2 Spark Therapeutics Business Overview
11.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Introduction
11.7.4 Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.7.5 Spark Therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Details
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Introduction
11.8.4 Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.8.5 Akcea Therapeutics Recent Development
11.9 bluebird bio
11.9.1 bluebird bio Company Details
11.9.2 bluebird bio Business Overview
11.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Introduction
11.9.4 bluebird bio Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.9.5 bluebird bio Recent Development
11.10 Sunway Biotech
11.10.1 Sunway Biotech Company Details
11.10.2 Sunway Biotech Business Overview
11.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Introduction
11.10.4 Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.10.5 Sunway Biotech Recent Development
11.11 SIBIONO
11.11.1 SIBIONO Company Details
11.11.2 SIBIONO Business Overview
11.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Introduction
11.11.4 SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.11.5 SIBIONO Recent Development
11.12 AnGes
11.12.1 AnGes Company Details
11.12.2 AnGes Business Overview
11.12.3 AnGes Gene Therapy On Cardiovascular Disease Introduction
11.12.4 AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.12.5 AnGes Recent Development
11.13 Orchard Therapeutics
11.13.1 Orchard Therapeutics Company Details
11.13.2 Orchard Therapeutics Business Overview
11.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Introduction
11.13.4 Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.13.5 Orchard Therapeutics Recent Development
11.14 Human Stem Cells Institute
11.14.1 Human Stem Cells Institute Company Details
11.14.2 Human Stem Cells Institute Business Overview
11.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Introduction
11.14.4 Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2020-2025)
11.14.5 Human Stem Cells Institute Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.